tbuckley/cabot-search huggingface dataset:
OC-029 Phenotype of Human Intrahepatic Innate Lymphoid Cell Subsets in Heatlh and Disease
Authors: P McDowell, S Roberts, HC Jeffery, S Hunter, YH Oo
Journal: Gut (2016)

<h3>Introduction</h3> Innate lymphoid cells (ILCs) involve in the initiation, regulation and resolution of inflammation. Although the role of ILCs in murine liver fibrosis and biliary proliferation has been reported, the phenotypic characteristics and functional role of these cells in human liver disease remains undefined. We explored the detailed phenotype of human intrahepatic ILCs to gain insight on their function. <h3>Methods</h3> Liver infiltrating lymphocytes from normal liver tissue, autoimmune liver diseases (AILD), alcoholic liver disease (ALD) and non-alcoholic steatohepatitis (NASH) explants were phenotyped with flow cytometry. <h3>Results</h3> Total intrahepatic ILC (CD3<sup>− </sup>lineage<sup>− </sup>CD45<sup>− </sup>CD127<sup>+ </sup>) comprised 1% (IQR 0.4–1.7%) of the CD3<sup>− </sup>CD45<sup>+</sup> population in normal liver and 0.4% for ALD/NASH and autoimmune livers. The ILC1 subset constituted the majority of intrahepatic ILC and its frequency is higher in normal liver compared to diseased livers (85% vs. 67%) (p &lt; 0.05). In contrast, CD161<sup>+</sup>CRTH2<sup>+ </sup>ILC2 subset and ILC3 subset frequency are higher in diseased livers compared to normal livers. Interestingly, frequency of ILC3 is significantly higher in ALD compared to normal liver (p &lt; 0.01). Intrahepatic ILC subsets are in activated and tissue resident state (CD69 75–90%). All subsets expressed the liver tissue homing chemokine receptor, CXCR3. Expression frequency is highest on diseased ILC1 (AILD 50%, ALD/NASH 56%,) compared to ILC2 (AILD 24%; ALD/NASH 15%) and ILC3 (AILD 38%, ALD/NASH 28%). Biliary tropic receptor CCR6 was expressed more highly by ILC subsets in diseased compared to normal livers. The fibronectin receptor, VLA5 and laminin receptor VLA6 were both highly expressed on all intrahepatic ILC subsets (60–90% and 55–80% respectively). In terms of the cytokine receptors expressed, on all ILC subsets, IL-6R was near undetectable (2%) and low expressions of ST2 (3–6%), IL-25R (2–5%) and IL-23R (2–7%) were detected. In contrast there was almost ubiquitous expression of IL18Ralpha. CD25 was also very highly expressed. Of note, CD25 was significantly higher in ILC1 and ILC3 subsets from normal compared to AILD (p &lt; 0.01) livers (40% vs. 80%; 66% vs. 93%) while intrahepatic ILC2 and ILC3 subsets in diseased states highly expressed CD25 (&gt;90%). Of likely functional importance, intrahepatic ILC1 expressed IFN-γ (40%) while ILC2 expressed IL-13 (20–50%) in diseased states. <h3>Conclusion</h3> We report for the first time the presence of all three ILC subsets within the human liver immune cell infiltrates. CXCR3<sup>+</sup> IFN-γ expressing ILC1 subset is enriched in both normal and inflamed diseased livers. Higher frequencies of CCR6<sup>+</sup> VLA5<sup>+</sup> VLA6<sup>+</sup> IL-13 expressing ILC2 are observed in diseased livers suggesting that this subset may play a role in biliary pathology and peri-biliary fibrosis. <h3>Disclosure of Interest</h3> None Declared
Molecular characterization and antibacterial effect of endophytic actinomycetes Nocardiopsis sp. GRG1 (KT235640) from brown algae against MDR strains of uropathogens
Authors: Govindan Rajivgandhi, Ramachandran Vijayan, Marikani Kannan, Malairaja Santhanakrishnan, Natesan Manoharan
Journal: Bioactive Materials (2016)

Our study is to evaluate the potential bioactive compound of Nocardiopsis sp. GRG1 (KT235640) and its antibacterial activity against multi drug resistant strains (MDRS) on urinary tract infections (UTIs). Two brown algae samples were collected and were subjected to isolation of endophytic actinomycetes. 100 strains of actinomycetes were isolated from algal samples based on observation of morphology and physiological characters. 40 strains were active in antagonistic activity against various clinical pathogens. Among the strains, 10 showed better antimicrobial activity against MDRS on UTIs. The secondary metabolite of Nocardiopsis sp. GRG1 (KT235640) has showed tremendous antibacterial activity against UTI pathogens compared to other strains. Influence of various growth parameters were used for synthesis of secondary metabolites, such as optimum pH 7, incubation time 5–7 days, temperature (30 °C), salinity (5%), fructose and mannitol as the suitable carbon and nitrogen sources. At 100 μg/ml concentration MIC of Nocardiopsis sp. GRG1 (KT235640) showed highest percentage of inhibition against Proteus mirabilis (85%), and E.coli, Staphylococcus auerues, Psuedomonas aeroginasa, Enterobactor sp and Coagulinase negative staphylococci 78–85% respectively.
A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma
Authors: Muzaffar H. Qazilbash, Rima M. Saliba, Matteo Pelosini, Chitra M Hosing, Floralyn L Mendoza, Eric Han, Michael Wang, Donna M. Weber, Amin M. Alousi, Paolo Anderlini, Partow Kebriaei, Issa F. Khouri, Uday R Popat, Marcos De Lima, Robert Z. Orlowski, Richard E. Champlin, Sergio A. Giralt
Journal: Blood (2008)
Green, Yellow, and Red risk perception in everyday life – a communication tool
Authors: A. Stensgaard, A. DunnGalvin, D. Nielsen, M. Munch, C. Bindslev‐Jensen
Journal: Allergy (2016)

Adolescents have the highest risk for food allergy-related fatalities. Our main aim was to investigate the level of risk in everyday social situations as perceived by adolescents/young adults with peanut allergy, their families, and their friends.The web-based 'Colours Of Risks' (COR) questionnaire was completed by 70 patients (aged 12-23 years), 103 mothers and fathers, 31 siblings (aged 12-26 years), and 42 friends (aged 12-24 years). COR deals with six main contexts (home, school/university, work, visiting/social activities, special occasions/parties, and vacations), each with 1-12 items. Response categories are green (I feel safe), yellow (I feel uncertain), or red (I feel everything is risky).There was a high level of agreement between participants in defining situations as safe, uncertain, or risky, but female patients and mothers rated fewer situations as safe compared to male patients and fathers. Being with close friends and family, and attending planned parties without alcohol were perceived as situations of low risk. While 94% of patients took an epinephrine auto-injector (EAI) into risky situations, only 65% took it into safe situations. In contrast to the close family, 31% of the friends did not know the patient had an EAI, and fewer knew how to administer the EAI.Young adults with peanut allergy face challenges when moving from the safe home with ready assistance if needed, to independence with unpredictable surroundings and less certain help. Perceived 'safe' situations may in fact be the riskiest, as patients often do not take the EAI with them.
Genetic Modification of Multi Leukemia Antigen-Specific Cytotoxic T Lymphocytes (CTL) to Enhance In Vivo Safety and Persistency
Authors: Fabian Zohren, Maria R Imperato, Anurathapan Usanarat, David M Spencer, Helen E. Heslop, Malcolm K. Brenner, Cliona M. Rooney, Ann M. Leen, Juan F Vera, Ulrike Gerdemann
Journal: Blood (2011)
Understanding the delayed prescribing of antibiotics for respiratory tract infection in primary care: a qualitative analysis
Authors: R Ryves, C Eyles, M Moore, L McDermott, P Little, G M Leydon.
Journal: BMJ (2016)

Objective To identify general practitioner (GP) views and understanding on the use of delayed prescribing in primary care.

Design Qualitative semistructured telephone interview study.

Setting Primary care general practices in England.

Participants 32 GPs from identified high-prescribing and low-prescribing general practices in England.

Method Semistructured telephone interviews were conducted with GPs identified from practices within clinical commissioning groups with the highest and lowest prescribing rates in England. A thematic analysis of the data was conducted to generate themes.

Results All GPs had a good understanding of respiratory tract infection (RTI) management and how the delayed prescribing approach could be used in primary care. However, GPs highlighted factors that were influential as to whether delayed prescribing was successfully carried out during the consultation. These included the increase in evidence of antimicrobial resistance, and GPs' prior experiences of using delayed prescribing during the consultation. The patient–practitioner relationship could also influence treatment outcomes for RTI, and a lack of an agreed prescribing strategy within and between practices was considered to be of significance to GPs. Participants expressed that a lack of feedback on prescribing data at an individual and practice level made it difficult to know if delayed prescribing strategies were successful in reducing unnecessary consumption. GPs agreed that coherent and uniform training and guidelines would be of some benefit to ensure consistent prescribing throughout the UK.

Conclusions Delayed prescribing is encouraged in primary care, but is not always implemented successfully. Greater uniformity within and between practices in the UK is needed to operationalise delayed prescribing, as well as providing feedback on the uptake of antibiotics. Finally, GPs may need further guidance on how to answer the concerns of patients without interpreting these questions as a demand for antibiotics, as well as educating the patient about antimicrobial resistance and supporting a good patient–practitioner relationship.
Bile Acids Protect Expanding Hematopoietic Stem Cells from Unfolded Protein Stress in Fetal Liver
Authors: Valgardur Sigurdsson, Hajime Takei, Svetlana Soboleva, Visnja Radulovic, Roman Galeev, Kavitha Siva, L. M. Fredrik Leeb-Lundberg, Takashi Iida, Hiroshi Nittono, Kenichi Miharada
Journal: Blood (2015)
Comorbidity as Prognostic Variable in MDS: Comparative Evaluation of the HCT-CI and CCI in a Core Data Set of 582 Patients of the Austrian MDS Platform.
Authors: Wolfgang R Sperr, Friedrich Wimazal, Michael Kundi, Christian Baumgartner, Thomas Noesslinger, Anabel Makrai, Reinhard Stauder, Otto Krieger, Michael Pfeilstocker, Peter Valent
Journal: Blood (2008)
SAT0512 Does Switching from One Non-Steroidal Anti-Inflammatory Drug (NSAID) To Another Improve Pain Control?
Authors: A. Karateev, N. Gontarenko, A. Tsurgan
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> NSAIDs - the main medications for control of musculoskeletal pain in rheumatic diseases (RD). However, their use does not always lead to a significant reduction of pain and may be accompanied by side effects. There is a need to replace the first NSAID with another in many patients. <h3>Objectives</h3> To evaluate the results of the use of the selective COX-2 inhibitor etoricoxib in patients with acute/subacute pain related to background RD despite using other NSAIDs. <h3>Methods</h3> A group of patients of 1566 patients (63.5% women and 31.1% men, age 48.8 ± 13.9 years) with acute/subacute pain associated with RD (mainly osteoarthritis and back pain) was included in an open-label study. The criterion for selection of patients was dissatisfaction with the treatment (10 cm VAS pain &gt;3 cm) by background NSAIDs. The patients mainly used diclofenac (24.5%), nimesulide (27.2%) and meloxicam (25.6%). After inclusion in the study all patients started etoricoxib instead of other NSAIDs. The dose and duration of treatment were determined by a physician: the majority of patients (59.6%) took etoricoxib 90 mg/day. The results of treatment were assessed after 2 weeks. <h3>Results</h3> After start of treatment with etoricoxib a significant improvement was observed in the majority of patients. Pain decreased from 6.21 ± 1.4 to 1.93 ± 1.3 cm VAS. The complete pain relief was achieved in 12.5% of patients, 58.3% achieved low intensity of pain (VAS &lt;2 cm). Additional therapy for symptom control (muscle relaxants, other analgesics, local injections of glucocorticoids, and others) needed in 31.2% of patients. The best effect was observed when using a higher dose of etoricoxib: decrease of pain intensity on 120 mg, 90 mg and 60 mg per day was 4.77 ± 1.88, 4.69 ± 2.01 and 3.50 ± 1.48 cm VAS respectively (the difference between 120 and 60 mg/day, 90 and 60 mg/day was significant, p&lt;0.001). Treatment tolerability was assessed as “good” in 62.7%, "satisfactory" in 36.7% and "bad" in 0.6% of patients. Adverse events were reported in 55 patients (3.5%), mainly dyspepsia – in 21 (1.3%) and arterial hypertension - in 27 patients (1.7%). <h3>Conclusions</h3> Switching from previous therapy with NSAIDs to etoricoxib provides an effective reduction of acute/subacute pain. High doses etoricoxib are more effective. Short-term use of etoricoxib rarely causes adverse events. <h3>Disclosure of Interest</h3> None declared
Infant Acute Lymphoblastic Leukemias Are Pan-Sensitive to Obatoclax Across molecular/Cytogenetic Subtypes, Especially MLL-ENL, and gene Expression Profiles Determine Obatoclax IC50: A Report on the Children's Oncology Group (COG) P9407 Trial
Authors: Karen A. Urtishak, Li-San Wang, Richard Harvey, Susan R Atlas, I-Ming L. Chen, Blaine W. Robinson, Lea Moukarzel, Kajia Cao, Meenakshi Devidas, Andrew J. Carroll, Nyla A. Heerema, Stephen Hunger, Gregory H. Reaman, Joanne M. Hilden, Bruce Camitta, Naomi Winick, William L. Carroll, Alena Y. Zhang, Lori Cory, Steven Mc Veigh, Jeffery S. Barrett, Zoann E. Dreyer, Cheryl L. Willman, Carolyn A. Felix
Journal: Blood (2010)
Cytogenetic and Molecular Characterization of Extramedullary Disease (EMD) in Patients (pts) with Acute Myeloid Leukemia (AML).
Authors: Naveen Pemmaraju, Hagop M. Kantarjian, Kathy M. Tran, Syed M. Kazmi, Tapan M. Kadia, Gautam Borthakur, Srdan Verstovsek, Susan O'Brien, Guillermo Garcia-Manero, Zeev Estrov, Stefan Faderl, Farhad Ravandi, Sherry A. Pierce, Jorge E. Cortes, Alfonso Quintas-Cardama
Journal: Blood (2012)
FRI0364 Does An Elevated Serum Immunoglobulin A Level Predict The Course of Adult IGA Vasculitis?: Table 1.
Authors: A. Hočevar, J. Ostrovršnik, Ž. Rotar, M. Tomšič
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> Our objective was to evaluate the impact of serum IgA level on the clinical presentation and severity of adult IgA vasculitis (IgAV). <h3>Methods</h3> We prospectively collected data on newly diagnosed histologically proven adult IgAV cases between January 2013 and December 2015 at our at our secondary/tertiary rheumatology centre. Patients were stratified according to the serum level of IgA into two groups (elevated IgA (&gt;4.10 g/l) vs. normal IgA (0.7–4.10 g/l)). <h3>Results</h3> During the 36 month observation period, 92 new adult IgAV cases (54% male) were identified. The median age was 65.8 (interquartile range (IQR) 48.7–77.3, range 19–88) years and the median disease duration (IQR, range) 7 (6–21, 2–120) days. The serum level of IgA was elevated in 39 (42.4%) cases. The characteristics of IgAV groups with increased and with normal serum IgA level at presentation and at follow-up are presented in Table 1. Follow-up data were available for 59 (24 had elevated IgA) patients, with a median (IQR) follow-up of 7.2 (5.0–14.5) months. <h3>Conclusions</h3> Elevated IgA serum level does not seem to have any significant impact on the disease manifestations and severity of adult IgAV. However, there was a trend toward less frequent antecedent infections and more frequent malignancy development in the group with high serum IgA. <h3>Disclosure of Interest</h3> None declared
SAT0526 Self-Management in Chronic Neck Pain Caused by Congenital Cervical Vertebra Block: A Randomized Clinical Trial
Authors: R. Traistaru, A.M. Bumbea, D. Kamal, R. Marcu, O. Rogoveanu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Single congenital fusions are common anomalies, found most often at the C2–3 and C5–6 levels had moderate or severe degenerative changes in their cervical spines, or displayed signs of cervical instability. There is no motion at the level of congenital block vertebrae, as noted in flexion and extension radiographic analysis, resulting in excessive mobility and early degenerative changes at the adjacent unfused motion segments. <h3>Objectives</h3> The aim of our single blind, randomized controlled study was to assess the efficacy of comprehensive home exercise program on neck pain and physical performance in patients with block vertebrae in lower cervical segments (C5-C6 and C6-C7). <h3>Methods</h3> 36 patients with chronic neck pain and cervical block vertebrae were randomly assigned into exercise home group (G1, 19 patients) and second group (G2, 17 patients - noncompliant to exercise program). All patients were complete assessed (clinical, imagistic, functional). Kinetic program (first light positive exercise, next gradually strengthening exercises for the all cervical muscle exercise, one set of 10 repetitions each direction, twice a day and neck school exercises) was initiated in rehabilitation clinic. Duration of follow-up was 16 weeks after start of the intervention. At 4 and 16 weeks an independent physiotherapist unaware of the treatment allocation performed outcome assessments - pain (VAS) and Neck Disability Index (NDI) for functional status. <h3>Results</h3> Comparing week 16 with baseline, pain improved significantly (<i>p</i>&lt;0.05). Significant improvement in NDI scores for pain and functional status were found at week 4 and week 16 in the G1 compared to baseline. At 16 weeks, 16 (84.2%) patients mentioned their functional status as improved and only 3 (15.8%) as similar at baseline. <h3>Conclusions</h3> The exercise program performed daily led to improvements in pain and physical measures. Optimal neck care in congenital cervical vertebra block includes pain-relieving exercises that also help restore neck posture, limitation of the neck movement and the muscular weakness. These techniques can help recover and provide good control against future symptoms (atrophy and neurological sensory loss, myelopathy). <h3>Disclosure of Interest</h3> None declared
SP0034 Development of The EULAR Recommendations for The Use of Imaging in Osteoarthritis Clinical Practice
Authors: A. Iagnocco
Journal: Annals of the Rheumatic Diseases (2016)

In the last few years the application of musculoskeletal imaging in rheumatology clinical practicehas become more widespread. However recommendations on its use in osteoarthritis (OA) are lacking. <h3>Objective</h3> To develop evidence-based recommendations for the use of imaging in OA clinical practice <h3>Methods</h3> After the project was approved by the EULAR Executive Committee, a task force of experts in the field of OA and imaging met in order to plan the strategy for a systematic literature review (SLR), subsequently conducted by a research fellow under the supervision of the conveners and the methodologist of the group. The task force identified areas of application of imaging in OA clinical practice and developed the research questions to drive the SLR. The imaging modalities (conventional radiography, ultrasound, magnetic resonance imaging, computed tomography, radioisotope scan) and joints (knee, hip, hand and foot) were first identified. Second, the role of imaging in the diagnosis of OA, identification of OA characteristics, detection of other diseases, managing OA, defining its prognosis, monitoring the disease progression as well asguiding treatment was addressed. A systematic search was performed separately for each question and site using PubMed and Embase. <h3>Results</h3> From an initial SLR, 6858 references were found, 1317 papers were reviewed in detail and 380 of them were included. Furthermore, to investigate evidence not addressed by the first SLR,the task force required additional SLRs to evaluate the accuracy and efficacy of imaging-guided compared to blind injections and the comparison of different radiographic projections. For the first SLR, 25 papers out of 5379 abstracts were assessed and 8 included, while for the comparison of different projections 53 papers out of 4774 abstracts were reviewed, with the inclusion of 31 papers. After analysing the results of the SLRs and giving their expert opinion, the task force developed consensus recommendations. These covered different areas such as the lack of need for diagnostic imaging in patients with typical symptoms, the role of imaging in differential diagnosis, the use of imaging in monitoring OA when no significant therapeutic modification isrelated, the first choice imaging modality, how to acquire images, the influence of different joints on selecting the type and use of imaging modalities, and the role of imaging in guiding local injections. Future research recommendations were developed based on areas where there was a paucity of literature. <h3>Conclusions</h3> EULAR recommendations for the use of imaging in osteoarthritis clinical practice have been developed thus filling a knowledge gap in the field. <h3>Key messages</h3> –Recommendations on the use of imaging in OA clinical practice are lacking. –Based on the results of a SLR and expert opinion, recommendations on the use of imaging in the clinical management of OA were developed. <h3>Disclosure of Interest</h3> None declared
Fenretinide (4HPR) Inhibits Growth of Myeloma Cells in Their Microenvironment and Is a Potent Inhibitor of Angiogenesis and Osteoclastogenesis.
Authors: Xin Li, Wen Ling, Rinku Saha, Paul Perkins, Angela Pennisi, Shmuel Yaccoby
Journal: Blood (2006)
Aldehyde Dehydrogenase (ALDH) Activity Resolves Neuroblastoma (NB) Cells and Hematopoietic Stem and Progenitor Cells (HPC) in Graft Material: Potential Method for Clinical Purging.
Authors: Sandra J. Foster, Lisa Winstead, Timothy A. Driscoll, Andrew E. Balber
Journal: Blood (2004)
FRI0534 Studying Bone Mineral Density Loss in Clinically Suspect Arthralgia, Associations with Subclinical Inflammation and Progression To Clinical Arthritis
Authors: L. Mangnus, H.W. van Steenbergen, M. Reijnierse, J. Kälvesten, A.H.M. van der Helm-van Mil
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Peripheral bone mineral density (BMD) can be decreased in early rheumatoid arthritis but it is unknown if BMD loss emerges already before arthritis is clinically apparent. <h3>Objectives</h3> We aimed to study if BMD loss occurs in patients with clinically suspect arthralgia (CSA), if it is associated with progression to clinical arthritis and if it is associated with MRI-detected subclinical inflammation. <h3>Methods</h3> Patients with CSA had arthralgia for &lt;1 year and were suspect to progress to RA according to their rheumatologists. At baseline a 1.5T MRI was performed of unilateral MCP, wrist and MTP-joints and scored on synovitis, bone marrow edema and tenosynovitis;. summing these features yielded the MRI-inflammation score. Digital X-ray radiogrammetry (DXR) was used to measure BMD on two sequential conventional hand radiographs (mean interval between radiographs 4.4 months). The change in BMD was studied; BMD loss was defined as decrease of ≥2.5 mg/cm<sup>2</sup>/month. Patients were followed on arthritis development for median 18.4 months. <h3>Results</h3> In CSA-patients (n=108) change in BMD was negatively associated with age (β=-0.03, p=0.007). Within CSA-patients BMD loss was associated with arthritis development (adjusted for age HR=6.1, 95%CI=1.7;21.4) and was most frequently measured in the months before clinical arthritis development. The MRI-inflammation scores were associated with the change in BMD (adjusted for age β=-0.05, p=0.047). The MRI-inflammation score and BMD loss were both independently associated with arthritis development (HR=1.1 95%CI=1.1;1.2 and HR=4.6 95%CI=1.2;17.2 respectively). <h3>Conclusions</h3> In CSA-patients BMD loss is associated with MRI-detectable subclinical inflammation and with progression to clinical arthritis. <h3>Disclosure of Interest</h3> L. Mangnus: None declared, H. van Steenbergen: None declared, M. Reijnierse: None declared, J. Kälvesten Employee of: Sectra AB, A. van der Helm-van Mil: None declared